Irhythm Holdings, Inc. · NASDAQ:IRTC
Irhythm — William Blair 46th Annual Growth Stock Conference (June 2026)
26 slides from Irhythm's conference presentation, Jun 2, 2026
Slide 1: iRhythm Holdings William Blair 46th Annual Growth Stock Conference
iRhythm Holdings William Blair 46th Annual Growth Stock Conference June 2, 2026 © 2026 iRhythm Holdings, Inc. 1
Slide 2: Cautionary statement re forward-looking statements, non-GAAP measures and other matters
Cautionary statement re forward-looking statements, non-GAAP measures and other matters Certain data in this presentation was obtained from various external sources, and neither “iRhythm Holdings, Inc. You should not rely upon forward-looking statements as predictions of future events. Although we b
Slide 3: Addressing major challenges and opportunities in healthcare
Addressing major challenges and opportunities in healthcare THE PROBLEM MARKET CATALYSTS THE ACCESS GAP IRHY THM’S IMPACT Heart disease is the #1 Aging population, consumer 46.3% of all U.S. counties – 20 years advancing cardiac cause of death globally. arrhythmia awareness, and 86.2% of rural count
Slide 4: At the Heart of it: The Moat - iRhythm is more than a device
At the Heart of it: The Moat - iRhythm is more than a device Device Data Services PATENTED WEARABLE ADVANCED SOFTWARE AND AI CLINICAL SERVICE & BIOSENSORS APPLIED TO A RICH DATASET OPERATIONAL WORKFLOW Single-use monitor designed for 2nd Generation, FDA-cleared, Convenient ordering and delivery clin
Slide 5: 27+ million potential patients; $199.4 million first quarter 2026 revenue
27+ million $199.4 million Potential patients in the United First quarter 2026 revenue, States who could benefit from a 25.7% increase year-over-year ambulatory cardiac monitoring* 2.6 million 3.2 million tests Patient reports posted annually Target market opportunity across prioritized EU and APAC
Slide 6: ACM market is evolving with runway for durable growth
ACM market is evolving with runway for durable growth TREMENDOUS MARKET EXPANSION POTENTIAL AHEAD MARKET LEADERSHIP IN LTCM : 72% market share in LTCM (of 3.5 million tests in US today growing high teens % YOY) with ~ 27 million undiagnosed US patients at elevated risk SHORT DURATION MONITORS YET TO
Slide 7: Primary care adoption key to accessing expansive TAM
Primary care adoption key to accessing expansive TAM IRHY THM UNIQUELY POSITIONED TOTAL MARKET CLAIMS BY APPROACHING PRIMARY CARE VIA TO WIN IN PRIMARY CARE MODALIT Y & SPECIALT Y T WO-PRONGED STRATEGY MCT ✓ Market leader in LTCM, the preferred modality EVENT Land-and-expand within ✓ Rule-in/rule-ou
Slide 8: Precise, proactive monitoring enables population health management
Precise, proactive monitoring enables population health management… ARRHY THMIA PATIENTS USE THE HEALTHCARE SYSTEM AT A MUCH HIGHER RATE COMPARED COPD TO NON-ARRHY THMIA PATIENTS 1 SLEEP APNEA: 11.7 million US prevalence of 40.1 TAM 2.0M2 million, with up to 80% of Arrhythmia patients hospitalized m
Slide 9: …which is being embraced by innovative channel partnerships
…which is being embraced by Direct-to- innovative channel partnerships Consumer Partners Innovative Virtual Care Primary Care Providers ~85% of patients in representative customer programs Direct & Employer Value Based Care Models Home-Based Testing had at least one arrhythmia identified1 Value-Base
Slide 10: Next-gen MCT designed to extend our category leadership
Next-gen MCT designed to extend our category leadership Zio AT® Zio MCT** (Not yet FDA cleared, Expected H1’27) Improved form factor Device form factor Legacy patch technology • Same platform as Zio monitor • Better adhesion and battery Wear duration Up to 14 days Up to 21 days Auto-detects and tran
Slide 11: Significant runway in international expansion
Significant runway in international expansion PRIORITIZED EU COUNTRIES Switzerland, Spain, Austria, UNITED KINGDOM and the Netherlands JAPAN Early commercialization Early commercialization Early commercialization 700,000 900,000 1,600,000 Ambulatory cardiac monitoring Ambulatory cardiac monitoring A
Slide 12: Durable AI advantage creates high barriers to entry
Durable AI advantage creates high barriers to entry Clinical-grade AI isn’t an algorithm, it’s an end-to-end, regulated platform built over decades PROPRIETARY DATASET + VALIDATED AI PLATFORM REGULATORY + QUALITY END-TO-END WORKFLOW SIGNAL QUALITY + CLINICAL ADVANTAGES + DISTRIBUTION >3B hours of cu
Slide 13: Comprehensive evidence generation supportive of clinical use cases
Comprehensive evidence generation supportive of clinical use cases CLINICAL OUTCOME ECONOMIC VALUE ADJACENT PATIENT SUPERIORT Y POPULATIONS CAMELOT and AVALON studies show Zio LTCM service associated with a In patients with T2D and/or COPD, Zio LTCM service demonstrate lower probability of inpatient
Slide 14: Next expansion opportunity: obstructive sleep apnea
Next expansion opportunity: obstructive sleep apnea SLEEP APNEA • Prevalence of sleep disorders1: 40.1 million • Large prevalence of undiagnosed sleep apnea missing a convenient diagnostic pathway for many PCPs • Natural evolution of iRhythm’s platform capabilities: • Up to 80% of AFib patients have
Slide 15: 1Q26 milestones reflective of execution and momentum
1Q26 milestones reflective of execution and momentum ACCELERATING BRINGING GENERATING MOMENTUM IN PROVIDING A INNOVATIVE PEER-REVIEWED EXECUTING WITH COMMERCIAL WINNING CUSTOMER PRODUCTS TO CLINICAL EXPANDING MARKET DISCIPLINE & BUSINESS EXPERIENCE MARKET EVIDENCE ACCESS EFFICIENCY $199.4 million re
Slide 16: First quarter 2026 financial performance
First quarter 2026 financial performance GLOBAL NET REVENUE GROSS PROFIT MARGIN (USD, MILLIONS) +25.7% Y/Y +210 bps Y/Y $208.9 $199.4 $192.9 71.2% 71.1% 70.9% 70.9% $186.7 $158.7 68.8% 1Q2025 2Q2025 3Q2025 4Q2025 1Q2026 1Q2025 2Q2025 3Q2025 4Q2025 1Q2026 ADJUSTED OPERATING EXPENSES * ADJUSTED EBITDA
Slide 17: 2026 outlook balances growth across near-term opportunities
2026 outlook balances growth across near-term opportunities U.S. CORE COMMERCIAL BUSINESS • Further expansion into PCP channel GLOBAL NET REVENUE (USD, MILLIONS) • New technologies (e.g., PFA) expand monitoring $875 – • MCT market expansion with continued innovation $885 $747.1 $591.8 INTERNATIONAL
Slide 18: Addressing the future focus of healthcare
Addressing Expanding core the future focus & unlocking of healthcare adjacent markets Growing revenue Driving through global market meaningful expansion improvements in financial profile
Slide 19: Appendix
Appendix
Slide 20: Reconciliation of net income (loss) to adjusted EBITDA
Reconciliation of net income (loss) to adjusted EBITDA Adjusted EBITDA is a non-GAAP financial measure and is presented for supplemental informational purposes only and should not be considered as an alternative or substitute to financial information presented in accordance with GAAP. Adjusted EBITD
Slide 21: Reconciliation of GAAP to non-GAAP financial information
Reconciliation of GAAP to non-GAAP financial information Adjusted EBITDA, adjusted net income (loss), adjusted net income (loss) per share, adjusted operating expenses, and free cash flow are non-GAAP financial measures and are presented for supplemental informational purposes only and should not be
Slide 22: Reconciliation of GAAP to non-GAAP financial information
Reconciliation of GAAP to non-GAAP financial information (USD, THOUSANDS) THREE MONTHS ENDED MARCH 31, ADJUSTED NET LOSS RECONCILIATION* 2026 2025 Net loss, as reported1 $ (13,933) $ (30,700) Business transformation costs 346 503 Intellectual property litigation costs2 3,689 832 Changes in fair valu
Slide 23: Reconciliation of GAAP to non-GAAP financial information
Reconciliation of GAAP to non-GAAP financial information (USD, THOUSANDS) THREE MONTHS ENDED MARCH 31, ADJUSTED OPERATING EXPENSES RECONCILIATION* 2026 2025 Operating expenses, as reported $ 157,538 $ 141,772 Business transformation costs (346) (503) Intellectual property litigation costs1 (3,689) (
Slide 24: Slide sources
SLIDE(S) SOURCES ‘Addressing major challenges • WHO, Cardiovascular Diseases Fact Sheet and opportunities in • American Heart Association, Circulation (Presidential Advisory on CVD Economic Burden, 2024) healthcare’ • AHRQ HCUP; healthcare cost analyses • HRS 2026 data; ACC Scientific Sessions • War
Slide 25: Slide sources
SLIDE(S) SOURCES iRhythm overview and ‘ACM US Core ACM Market Sizing market is evolving with • iRhythm estimates based off combination of Internal Data, Medicare Public-Use Files, IQVIA data, Definitive Healthcare data, Komodo Health data, and other runway for durable growth’ publicly-available info
Slide 26: Slide sources
SLIDE(S) SOURCES ‘Precise, proactive monitoring • Real World Evidence on Health Care Resource Utilization and Economic Burden of Arrhythmias in Patients with Diabetes and COPD. Abstract presented at: 2024 enables population health AHA Scientific Sessions; November 16 to 18, 2024; Chicago, IL. manage
iRhythm Holdings — William Blair 46th Annual Growth Stock Conference (June 2026) on 6ix